PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.50
Bid: 1,775.50
Ask: 1,776.00
Change: 0.50 (0.03%)
Spread: 0.50 (0.028%)
Open: 1,775.50
High: 1,778.50
Low: 1,769.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

Tue, 06th Apr 2021 14:54

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:

----------

GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - Hires Anne Beal as non-executive director, starting May 6. Beal will replace Lynn Elsenhans as chair of the Corporate Responsibility Committee, and Elsenhans will stay on the board for an additional year to allow for a handover. Beal is founder and chief executive officer of AbsoluteJOI Skincare. She spent six years at Harvard Medical School and Massachusetts General Hospital, instructing in paediatrics.

----------

Assura PLC - Warrington, England-based primary care property investor - Jenefer Greenwood will retire as non-executive director at Assura's July 6 annual general meeting. Hires Emma Cariaga, Noel Gordon and Sam Barrell as new non-executive directors, starting on May 1. Cariaga is joint head of Canada Water Development on the executive committee of British Land Co PLC. Gordon was global managing director at consultants Accenture. For the UK National Health Service, he was chair of NHS Digital and a non-executive director of NHS England. Barrell is chief operating officer of the Crick Institute, which supports biomedical research.

----------

Rosslyn Data Technologies PLC - London-based cloud enterprise data analytics platform - Chief Executive Officer Roger Bullen steps down from board, effective immediately, but will remain as an adviser for six months. Bullen served for five years as CEO and chief financial officer. Chief Customer Officer Paul Watts is promoted to CEO. Watts joined Rosslyn back in August and before that was CEO of Blue Prism KK Japan, a robotic process automation company. Both Chair James Appleby and CFO Ash Mehta will take on additional responsibilities. Rosslyn also says it expects its results for the financial year ending April 30 to be in line with market expectations. It will issue a trading update in late May.

----------

Celtic PLC - Glasgow football club - Confirms that Dominic McKay will join Celtic on April 19 before replacing retiring Peter Lawwell as chief executive on July 1. Scottish Rugby confirmed that McKay will leave as chief operating officer on April 16, following a successful handover. McKay, who also was chair of the Guinness Pro14 annual rugby union competition, will join the Celtic board.

----------

Amryt Pharma PLC - London-based biopharmaceutical firm focused on rare and orphan diseases - Hires Sheila Frame as president for the Americas. Frame has held senior positions at Novartis AG, Bristol-Myers Squibb Co and AstraZeneca PLC.

----------

MyHealthChecked PLC - Cardiff-based consumer home-testing healthcare - Peter Dines steps down as non-executive director on Tuesday. Dines is chief operating officer of Mercia Asset Management PLC, whose funds have a 28% stake in MyHealthChecked. He is standing down to focus on other portfolio companies.

----------

Northamber PLC - Chessington, Surrey-based audio-visual and information technology distributor - Promotes Finance Director Tony Lee to board and hires Riccardo Reggio as a non-executive director, both from last Thursday. Lee re-joined Northamber in August of last year, having previously been finance director from 2003 to 2005. Reggio is a corporate strategy and acquisitions adviser who worked at Monitor Group for 15 years.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.